VANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc Reducer™ (“Reducer”). The two analyses, authored by Americo Cicchetti, Graduate School of Health Economics and Management (ALTEMS) at the Catholic University […]
Coronary/Structural Heart
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and […]
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
SUNNYVALE, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. It is believed […]
AnaCardio exercises option to license a program in heart failure from Helsinn
AnaCardio exercises option to license a program in heart failure from Helsinn Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has […]
SomaLogic to provide 105 million protein measurements from 15,000 samples as part of the Multi-Ethnic Study of Atherosclerosis (MESA) Study
Data will be available to researchers studying a wide range of disease states BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) — SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the Multi-Ethnic Study of Atherosclerosis (MESA) study beginning in the […]
Cleerly Named to NYC Digital Health 100 by New York City Health Business Leaders
Organization recognizes the most promising and innovative health startups in New York NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to New York’s healthcare ecosystem, has recognized the company on […]
Paragonix Technologies LUNGguard™ Used in Record Cross-Country Donor Lung Transplant Case
Device enables donor lungs to safely travel unprecedented distance of 4,788 Miles with a total ischemic time of over 13 hours CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies announces a milestone achievement for its Paragonix LUNGguard™ System as the device safely completed a record distance for donor lung transport from Alaska to North Carolina. The longest […]
Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
Aficamten Reduced LVOT Gradients in Patients on Disopyramide With No Instances of Left Ventricular Ejection Fraction Below 50% Findings Support Inclusion of Patients on Disopyramide in SEQUOIA-HCM SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohort 3 of […]
Englewood Health Receives Prestigious National Certification for Heart Valve Program
Bergen County’s first hospital to earn recognition from the American College of Cardiology for Transcatheter Valve ENGLEWOOD, N.J., Feb. 1, 2022 /PRNewswire/ — Englewood Health has been recognized by the American College of Cardiology (ACC) with the Transcatheter Valve Certification. This mark of distinction reflects the accomplishments of the Structural Heart and […]
Artivion Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in The Annals of Thoracic Surgery
Results Presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons ATLANTA, Jan. 31, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in The Annals of Thoracic Surgery, the official journal of The Society […]



